Nutritional management is important for patients with cancer cachexia. The goals of nutrition intervention are weight stabilization and improved quality of life and survival. Nutrition screening using a validated tool can identify patients in need of comprehensive assessment using the PG-SGA. A nutrition prescription including increased protein, energy, and eicosapentaenoic acid (EPA) can improve intake and attenuate weight loss. Regular nutrition counseling and high protein supplements are effective for implementation. Outcomes like intake and weight loss can be positively impacted, though effects on quality of life and survival require longer-term studies.
Stacy Kennedy, MPH, RD/LDN, CSO, Senior Clinical Nutritionist at Dana-Farber Cancer Institute/Brigham & Women's Hospital, offers nutrition advice for ovarian cancer patients and survivors.
Nutrition is very important yet neglected in field of oncology.
Majority of healthcare providers know and practice very little on this burning issue!
It is proven that nutrition impacts on overall survival, treatment outcome & recovery in oncology.
This presentation will give you brief information regarding importance and need of nutrition in Oncology.
Nutrition in Cancer Prevention and TreatmentTim Crowe
This presentation will help you to understand the influence that dietary and lifestyle factors play in the prevention and causation of cancer. It outlines the important nutritional considerations for patients undergoing treatment for cancer and reviews procedures to improve patient safety by knowing the risks and benefits of antioxidant supplementation during cancer treatment
“Cancer Anorexia Cachexia (originally Cancer Cachexia) is a multifactorial syndrome defined by:
Ongoing loss of skeletal muscle mass (with or without loss of fat mass)
Cannot be fully reversed by conventional nutritional support
Leads to progressive functional impairment”.
Stacy Kennedy, MPH, RD/LDN, CSO, Senior Clinical Nutritionist at Dana-Farber Cancer Institute/Brigham & Women's Hospital, offers nutrition advice for ovarian cancer patients and survivors.
Nutrition is very important yet neglected in field of oncology.
Majority of healthcare providers know and practice very little on this burning issue!
It is proven that nutrition impacts on overall survival, treatment outcome & recovery in oncology.
This presentation will give you brief information regarding importance and need of nutrition in Oncology.
Nutrition in Cancer Prevention and TreatmentTim Crowe
This presentation will help you to understand the influence that dietary and lifestyle factors play in the prevention and causation of cancer. It outlines the important nutritional considerations for patients undergoing treatment for cancer and reviews procedures to improve patient safety by knowing the risks and benefits of antioxidant supplementation during cancer treatment
“Cancer Anorexia Cachexia (originally Cancer Cachexia) is a multifactorial syndrome defined by:
Ongoing loss of skeletal muscle mass (with or without loss of fat mass)
Cannot be fully reversed by conventional nutritional support
Leads to progressive functional impairment”.
29Oct14 - ILC Global Alliance Ageing and Mobility SymposiumILC- UK
This event was a half day symposium which showcased international research by ILC Global Alliance members on frailty and mobility in old age.
This event took place as part of the ILC Global Alliance visit to the UK.
Speakers at the event included:
Rosy Pereyra – ILC-Dominican Republic: Sarcopenia: A forgotten cause of mobility problems in old age
Susana Concordo Harding – ILC-Singapore: Are we living longer and healthier? Exploring gender differences in health expectancy among older Singaporeans
Sebastiana Kalula – ILC-South Africa: Prevalence and risks factors for falls, and the impact on mobility in later life: The Cape Town study
Didier Halimi – ILC-France: MOBILAGE: how to maintain frail people mobility? An ongoing experiment at Broca Hospital in Paris.
Kunio Mizuta – ILC-Japan: Long-term care prevention in Japan: To maintain older people’s mobility
Lia Daichman – ILC-Argentina: Loss of mobility, loss of Autonomy, loss of quality of life
Iva Holmerová – ILC-Czech Republic: Local and national initiatives to support active ageing and improve quality of long-term care in the Czech Republic.
Panel members at the event included: Marieke van der Waal – ILC-Netherlands; Jayant Umranikar – ILC-India
Evidence-based guidelines for the nutritional management of adult oncology pa...milfamln
Webinar Objectives
1. The participant will be able to discuss the validity of malnutrition screening and nutrition assessment tools and their utilization in clinical oncology settings
2. The participant will be able to better utilize the Nutrition Care Process to provide appropriate and high-quality nutrition care to oncology patients
3. The participant will be able to describe the evidencebased relationships between nutritional status and morbidity and mortality outcomes in oncology
this is a detailed presentation on the principles of surgical nutrition. the presentation started with surgical metabolism and epidemiology of malnutrition in surgical patients. Furthermore, the aetiology of malnutrition was discussed in surgical patients. Finally, the various types of nutritional support, enteral and parenteral, was discussed under indications, types, access, advantages, disadvantages, complications and monitoring.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Are There Any Natural Remedies To Treat Syphilis.pdf
Nutritional managment of cachexia
1. CACHEXIA
Nutritional Management
Present by:
Sajjad Moradi-MS Student
Department of Community Nutrition, School of
Nutritional Sciences and Dietetics, Tehran Univer
sity of Medical Sciences (TUMS), Tehran, Iran
2. Introduction
• Cachexia : Greek word
Kakos : bad
Hexis : condition
• Characteristics
Weight loss
Lipolysis
Muscle wasting
Anorexia
Chronic nausea
Asthenia
Anemia
Electrolyte and water abnormalities
3. Introduction
• Diagnostic criteria for cachexia
• Unintentional weight loss (≥ 5%)
• BMI
• < 20 in those aged < 65 yrs
• < 22 in those aged ≥ 65 yrs
• Albumin < 3.5 g/dl
• Low fat-free mass (lowest 10%)
9. Glucose homeostasis
• Increase gluconeogenesis →Muscle and fat breakdown
• Increase glycolysis from muscle and tumour
• Increase lactate production
• Elevation of cori cycle activity → 300 kcal/day of energy loss
• Insulin resistance
• Increase counter regulatory hormone
• Decrease muscle glucose uptake
10. Protein metabolism
• Increase muscle catabolism
• Decrease muscle protein synthesis → Muscle wasting : asthenia
• Increase tumor protein synthesis
• Increase liver protein synthesis → Acute phase protein
11. Lipid metabolism
• Increase lipolysis
• Decrease lipogenesis
• Profound loss of adipose tissue
• Decrease lipoprotein lipase
• Decrease clearance of triglyceride
• Hypertriglyceridemia
• Low LDL, HDL
12. Cachexia VS anorexia (starvation)
• Body composition
Cachexia : loss of fat and skeletal muscle prior decrease food intake
Anorexia : loss of fat but small amount of muscle, after decrease food intake
• Weight loss
Cachexia : complex metabolic events
Anorexia : simple nutritional deficiency
• Treatment
Cachexia : multiple aspect
Anorexia : treatable by protein-calorie supplementation
13. Metabolic Alteration Starvation Cancer Cachexia
Protein turnover
Skeletal muscle catabolism
Nitrogen balance
Urinary nitrogen excretion
Decreased
Decreased
Negative
Decreased
Increased
Increased
Negative
Unchanged
Cachexia VS anorexia (starvation)
14. Role of Nutritional Management
• Improve the subjective quality of life
• Enhance anti-tumor treatment effects
• Reduce the adverse effects of
anti-tumor therapies
• Prevent & treat undernutrition
15.
16. Nutrition screening
• the process of identifying patients with characteristics commonly
associated with nutrition problems that may require comprehensive
nutrition assessment
• Simple, quick, reliable, valid and inexpensive
• Easily administered with minimal nutritional expertise
• Applicable to most patients and designed to incorporate only routine
data and tests available on admission
17. How should patients be identified for referral to the
dietitian in order to maximize nutritional
intervention opportunities?
• Identify “at risk” patients in oncology wards and
outpatient clinics using a nutrition screening tool su
ch as the Malnutrition Screening Tool (MST)that has
been validated for oncology patients.
18. Nutrition screening tools
• Malnutrition Screening Tool – Ferguson et al, 1999a, 1999b
• Malnutrition Universal Screening Tool – British Association of Parenteral
and Enteral Nutrition - Stratton et al, 2004
• Mini Nutrition Assessment-Short Form – Rubenstein et al, 2001
• Nutrition Risk Screening – Kondrup et al, 2003.
19. Nutrition screening tools problems
• Requiring specialized nutrition knowledge
• Biochemical parameters that may not be immediately available
• Requiring complex calculations
• Not being evaluated in terms of reliability or validity
20. PRACTICE TIPS
• If a patient has been referred to the dietitian by
other methods eg direct referral from medical
oncologist, nutrition screening is unnecessary –
proceed to nutrition assessment.
• Repeat nutrition screening during treatment at least
fortnightly for patients initially screened at low risk.
22. Subjective global assessment (SGA)
• Nutritional status on the base is of a medical history
weight change, dietary intake change, presence of gastrointestinal symptoms
that have persisted for greater than two weeks, functional capacity,
evidence of loss of subcutaneous fat, muscle wasting, oedema or ascites
SGA A: well nourished
SGA B:moderately or suspected of being malnourished
SGA C:severely malnourished
23. How should nutritional status be assessed?
• Use the scored Patient Generated - Subjective
Global Assessment (PG-SGA) as the nutrition a
ssessment tool in patients with cancer cachexi
a
24. Scored Patient Generated- Subjective
Global Assessment (PG-SGA)
• An adaptation of SGA specifically developed for use in the cancer
population
• Typical scores range from 0-47 with a higher score reflecting a
greater risk of malnutrition.
• Objective parameters : % weight loss, body mass index
• Measures of morbidity : survival, length of stay, quality of life
25. Use the PG-SGA to identify barriers to food
intake and facilitate optimal symptom control
• Dry mouth and/or swallowing problems - modify
texture as required and liaise with other allied health
professional support e.g. speech pathology.
• The Cancer Councils in each state provide valuable
patient resources describing the management of
nutrition impact symptoms.
26. Use the PG-SGA to identify barriers to food
intake and facilitate optimal symptom control
• Liaise with medical and support team and instigate
appropriate medical and nutrition treatment
• Taste changes, early satiety, aversion to smells - use
strategies to manage these
29. What are the goals of nutrition intervention
for patients with cancer cachexia?
• Weight stabilization is an appropriate goal for
patients with cancer cachexia
• Longer survival and improved quality of life than
those who continue to lose weight
30.
31. What is the nutrition prescription to
achieve these goals?
• Improving energy and protein intake
remains the first step in nutrition
intervention for weight losing cancer patie
nts
• Eicosapentaenoic acid (EPA)
improving energy and protein intake,
body composition, performance
status, quality of life
32. Nutrition Prescription
• Prior to commencing nutrition support, assess the
patient for risk of refeeding syndrome
• Protein and Energy Requirements
Energy intakes in excess of 120 kJ/kg/day
protein intake in excess of 1.4 g/kg/day
33. Nutrition Prescription
• Eicosapentaenoic acid (EPA)
1.4 – 2 g EPA/day -at least four weeks to achieve clinical
benefit.
• 8-11 capsules of fish oil (180 mg EPA/capsule)
• 300 - 400 g oily fish
• 310-445ml of a high protein energy supplement enriched
with EPA (0.45g EPA/100ml)
34. What are effective methods of
implementation to ensure positive outcomes?
• Nutrition counselling assists cancer patients to
optimize their intake.
• Regular nutrition intervention improves clinical
outcomes
• High protein and energy supplements play a valuable
role in improving intake and do not simply take the
place of usual meals.
35. Implementation of high protein, high
energy dietary advice
• Discuss good sources of protein in the diet – meat, fish and poultry,
and encourage with at least one serve a day.
• If protein intake is reduced due to taste changes emphasize good oral
hygiene, encourage with alternative sources of protein – eggs, dairy,
legumes and nuts, suggest marinating meats in juice or wine to
disguise a bitter taste
36. Implementation of high protein, high
energy dietary advice
• For patients with chewing and swallowing difficulties,
ensure protein in adequate in texture modified diets minced m
eats, pureed meat/chicken/fish, poached eggs, mashed beans
, peanut paste, lentil/bean soups
• Encourage patients to consider high protein/energy
supplements as an essential component of treatment.
37. Compliance issues with EPA to consider in
implementation
• High protein energy nutrition supplements
enriched with EPA– ensure adequate quantity
consumed each day, consider taste, consider cost
• Need to develop gastrointestinal tolerance to fish
oil and high protein energy supplements enriched
with EPA – gradually increase dose.
38. Does nutrition intervention improve
outcomes in patients with cancer cachexia?
• A range of outcomes can be measured in patients with
cancer cachexia including protein and energy intake,
appetite, weight, lean body mass, functional status, quality
of life and survival.
• Consumption of high protein energy supplement enriched
with EPA over a period of at least 8 weeks improves intake,
total energy expenditure and physical activity level and
attenuates weight loss in patients with cancer cachexia.
39. Does nutrition intervention improve
outcomes in patients with cancer cachexia?
• There is conflicting evidence about whether EPA
supplementation can improve quality of life, appetite, lean
body mass, and survival. This may be due to studies not being
conducted for long enough (at least 4 weeks) or because
improvement rather than attenuation was the outcome goal